Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 101–200 of 1,003
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Self-citationMechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there?
Fioravanti, A., Cantarini, L., Guidelli, G. M., & Galeazzi, M. (2011) · Rheumatology International · doi:10.1007/s00296-010-1628-6 · Cited by 250
Cooper, C., Chapurlat, R., Al-Daghri, N., Herrero-Beaumont, G., Bruyère, O., Rannou, F., Roth, R., Uebelhart, D., & Reginster, J.-Y. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00660-1 · Cited by 248
Renal adverse effects of nonsteroidal anti-inflammatory drugs
Harirforoosh, S., & Jamali, F. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903311023 · Cited by 261
“withdrew its product, rofecoxib, from the market [8] due to the outcomes of the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial [99].”
Background15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis
Myung, S.-J., Rerko, R. M., Yan, M., Platzer, P., Guda, K., Dotson, A., Lawrence, E., Dannenberg, A. J., Lovgren, A. K., Luo, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603235103 · Cited by 264
GSK-3β regulates cyclin D1 expression: A new target for chemotherapy
Takahashi-Yanaga, F., & Sasaguri, T. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.10.018 · Cited by 261
Cardioprotection by Adiponectin
Ouchi, N., Shibata, R., & Walsh, K. (2006) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2006.03.001 · Cited by 259
“Recent clinical trials reveal that treatment with selective COX-2 inhibitors results in an increased risk for cardiovascular complications including myocardial infarction (Bresalier et al. 2005, Solomon et al. 2005).”
BackgroundCyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Ferrer, M. D., Busquets-Cortés, C., Capó, X., Tejada, S., Tur, J. A., Pons, A., & Sureda, A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180514112124 · Cited by 246
Energy Balance, Host-Related Factors, and Cancer Progression
Hursting, S. D., & Berger, N. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.27.9935 · Cited by 252
“Nonsteroidal anti-inflammatory drugs have been shown to lower the risk of colon cancer,(137) but their use has been limited by adverse cardiovascular and/or GI effects.(138,139) Additional research is needed to identify different targets and classes of agents to interfere with inflammatory pathways without causing car…”
BackgroundTaketo, M. M., & Edelmann, W. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.049 · Cited by 249
For the International NSAID Consensus Group, Scarpignato, C., Lanas, A., Blandizzi, C., Lems, W. F., Hermann, M., & Hunt, R. H. (2015) · BMC Medicine · doi:10.1186/s12916-015-0285-8 · Cited by 236
“In RCTs, rofecoxib demonstrated a higher incidence of CV adverse events than naproxen in nonaspirin users with RA [109] or than placebo in patients with colorectal adenomas (Adenomatous Polyp Prevention on VioxxTM (APPROVe) trial) [170].”
BackgroundNF-κB pathways in the development and progression of colorectal cancer
Patel, M., Horgan, P. G., McMillan, D. C., & Edwards, J. (2018) · Translational Research · doi:10.1016/j.trsl.2018.02.002 · Cited by 250
Future directions in cancer prevention
Umar, A., Dunn, B. K., & Greenwald, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3397 · Cited by 248
Physiological Regulation of Prostaglandins in the Kidney
Hao, C.-M., & Breyer, M. D. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100614 · Cited by 247
Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin
GUTHIKONDA, S., LEV, E. I., PATEL, R., DELAO, T., BERGERON, A. L., DONG, J. ‐., & KLEIMAN, N. S. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02387.x · Cited by 245
S3-Leitlinie – Kolorektales Karzinom: Langversion 2.0 – November 2017–AWMF-Registernummer: 021/007OL
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T., Nothacker, M., Porschen, R., Rödel, C., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 241
Zochling, J., van der Heijde, D., Dougados, M., & Braun, J. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.041129 · Cited by 247
“Analysis of preliminary 3 year data from the Adenomatous Polyposis Prevention with Vioxx (APPROVe) study 85 showed an increased risk of serious thromboembolic events, including myocardial infarction or stroke in the rofecoxib treated group after 18 months of chronic dosage (RR 1.92, 95% CI 1.19 to…”
BackgroundInfluentialCOX-2 Inhibitors — Lessons in Drug Safety
Psaty, B. M., & Furberg, C. D. (2005) · New England Journal of Medicine · doi:10.1056/nejme058042 · Cited by 241
Moreno, J., Krishnan, A. V., Swami, S., Nonn, L., Peehl, D. M., & Feldman, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1435 · Cited by 237
“The clinical use of NSAIDs has recently become controversial because of the cardiovascular complications associated with the use of high doses of COX-2– selective NSAIDs for prolonged periods of time (54, 55).”
Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue
Varga, Z., Sabzwari, S. R. A., & Vargova, V. (2017) · Cureus · doi:10.7759/cureus.1144 · Cited by 231
“The relative risk difference became significant 18 months after the start of drug administration [13].”
BackgroundThe Involvement and Therapy Target of Immune Cells After Ischemic Stroke
Jian, Z., Liu, R., Zhu, X., Smerin, D., Zhong, Y., Gu, L., Fang, W., & Xiong, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02167 · Cited by 233
Lane, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp071112 · Cited by 233
Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk
Lo, B. (2015) · JAMA · doi:10.1001/jama.2015.292 · Cited by 233
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
Baron, J. A., Sandler, R. S., Bresalier, R. S., Lanas, A., Morton, D. G., Riddell, R., Iverson, E. R., & DeMets, D. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61490-7 · Cited by 232
Self-citationThe COXIB Experience: A Look in the Rearview Mirror
Marnett, L. J. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145638 · Cited by 228
Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks
Meek, I. L., Van de Laar, M. A. F. J., & E. Vonkeman, H. (2010) · Pharmaceuticals · doi:10.3390/ph3072146 · Cited by 220
“Cell damage, atherosclerotic plaques, and laminar shear forces selectively up-regulate the expression of COX-2 by endothelial cells in an attempt to maintain homoeostasis [38].”
BackgroundEmotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga
Grosser, T., Yu, Y., & FitzGerald, G. A. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-011209-153129 · Cited by 232
“Rofecoxib was withdrawn in September 2004, when an increase in the cardiovascular event rate was detected in the Adenomatous Polyp Prevention on Vioxx (APPROVe) study (84, 85).”
BackgroundMulti‐targeted therapy by curcumin: how spicy is it?
Goel, A., Jhurani, S., & Aggarwal, B. B. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700354 · Cited by 228
van der Heijde, D., Baraf, H. S. B., Ramos‐Remus, C., Calin, A., Weaver, A. L., Schiff, M., James, M., Markind, J. E., Reicin, A. S., Melian, A., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20985 · Cited by 230
Wehling, M. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1734-6 · Cited by 217
“Initially, it became obvious that COX II inhibitors may be at least as dangerous as non-specific NSAIDs in cardiovascular terms or be evenworse, as shown in the APPROVE trial [82].”
BackgroundSandborn, W. J., Stenson, W. F., Brynskov, J., Lorenz, R. G., Steidle, G. M., Robbins, J. L., Kent, J. D., & Bloom, B. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.002 · Cited by 231
McCormack, P. L. (2011) · Drugs · doi:10.2165/11208240-000000000-00000 · Cited by 224
Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system
Mitchell, J. A., & Kirkby, N. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14167 · Cited by 216
“However, it was only after the publication of the APPROVe trial (Bresalier et al., 2005) where rofecoxib was tested against placebo and showed increased cardiovascular events that this became a widely accepted side-effect and resulted in the withdrawal of the drug worldwide.”
BackgroundNSAIDs Inhibit Tumorigenesis, but How?
Gurpinar, E., Grizzle, W. E., & Piazza, G. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1573 · Cited by 216
“toxicity (24) that caused it to bewithdrawn from themarket and essentially halted other clinical trials of coxibs for cancer chemoprevention.”
Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development
Yoo, S. S., Jorgensen, T. J., Kennedy, A. R., Boice Jr, J. D., Shapiro, A., Hu, T. C.-C., Moyer, B. R., Grace, M. B., Kelloff, G. J., Fenech, M., et al. (2014) · Journal of Radiological Protection · doi:10.1088/0952-4746/34/2/r25 · Cited by 221
“…numerous human cancer prevention trials but many of these trials were stopped when results from the Adenomatous Polyp Prevention on Vioxx (APPROVe) (Bresalier et al 2005) and Adenoma Prevention with Celecoxib (Bertagnolli et al 2006) trials indicated that COX-2 inhibitors were associated with…”
BackgroundCyclooxygenase-2 as a target for anticancer drug development
Méric, J.-B., Rottey, S., Olaussen, K., Soria, J.-C., Khayat, D., Rixe, O., & Spano, J.-P. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.01.003 · Cited by 217
Celecoxib pathways: pharmacokinetics and pharmacodynamics
Gong, L., Thorn, C. F., Bertagnolli, M. M., Grosser, T., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834f94cb · Cited by 205
Angiogenic inhibitors: a new therapeutic strategy in oncology
Gasparini, G., Longo, R., Toi, M., & Ferrara, N. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0342 · Cited by 212
Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-27 · Cited by 214
“Risk increases have been observed with use of rofecoxib and celecoxib in clinical trials that were designed to evaluate their potential for treating arthritis or reducing colonic polyp recurrence [3-5], whereas risk decreases have been observed in observational studies that were designed to evaluate effects of these s…”
BackgroundHelin-Salmivaara, A. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl053 · Cited by 211
“45).(18) In the APC trial, the risk of serious cardiovascular events from celecoxib was dose-related.”
BackgroundThe heart and cardiovascular manifestations in rheumatoid arthritis
Voskuyl, A. E. (2006) · Rheumatology · doi:10.1093/rheumatology/kel313 · Cited by 213
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis
Wang, M., Zukas, A. M., Hui, Y., Ricciotti, E., Puré, E., & FitzGerald, G. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606586103 · Cited by 205
Stiller, C., & Hjemdahl, P. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13505 · Cited by 184
Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward
Menter, D. G., Schilsky, R. L., & DuBois, R. N. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0788 · Cited by 203
Heyworth, B. E., Lee, J. H., Kim, P. D., Lipton, C. B., Strauch, R. J., & Rosenwasser, M. P. (2008) · The Journal of Hand Surgery · doi:10.1016/j.jhsa.2007.10.009 · Cited by 204
NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species
Ghosh, R., Alajbegovic, A., & Gomes, A. V. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/536962 · Cited by 195
“The report of Adenomatous Polyp Prevention on Vioxx (APPROVe) trial on the adverse effect of rofecoxib on CVD ultimately led to the discontinuation of this drug in several countries [48].”
BackgroundNon‐Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction
Hernández‐Díaz, S., Varas‐Lorenzo, C., & García Rodríguez, L. A. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_302.x · Cited by 201
Chemoprevention of Colorectal Cancer
Katona, B. W., & Weiss, J. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.06.047 · Cited by 195
The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs
Grosser, T., Ricciotti, E., & FitzGerald, G. A. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.008 · Cited by 192
“Subsequently, this was confirmed in a series of randomized, placebo-controlled trials, designed to explore the utility of COX-2 inhibition in the prevention of colon cancer and post-operative analgesia [11, 12].”
BackgroundRole of nitric oxide in the gastrointestinal tract
Lanas, A. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2465 · Cited by 193
Fosbøl, E., Gislason, G., Jacobsen, S., Folke, F., Hansen, M., Schramm, T., Sørensen, R., Rasmussen, J., Andersen, S., Abildstrom, S., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.204 · Cited by 192
Targeting apoptosis pathways by Celecoxib in cancer
Jendrossek, V. (2013) · Cancer Letters · doi:10.1016/j.canlet.2011.01.012 · Cited by 194
“However, the observation about an increased rate of lifethreatening cardiovascular side effects in patients receiving long-term treatment with drugs of COXIB-family led to the withdrawl of two FDA-approved COXIBs, Rofecoxib and Valdecoxib, from the market in 2004/2005 and discredited the use of these compounds as anti…”
BackgroundListing, J., Strangfeld, A., Kekow, J., Schneider, M., Kapelle, A., Wassenberg, S., & Zink, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23281 · Cited by 195
COX-2 Inhibitors — A Lesson in Unexpected Problems
Drazen, J. M. (2005) · New England Journal of Medicine · doi:10.1056/nejme058038 · Cited by 199
Non‐Steroidal Anti‐Inflammatory Drugs, Cyclooxygenase‐2 and the Bone Healing Process
Vuolteenaho, K., Moilanen, T., & Moilanen, E. (2008) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00149.x · Cited by 191
Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Breazna, A., Kim, K., Tang, J., Rosenstein, R. B., Umar, A., Bagheri, D., et al. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0206 · Cited by 193
Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer
Zhang, G., Kodani, S., & Hammock, B. D. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.11.003 · Cited by 185
“However, chronic and high dose use of COX inhibitors can cause life-threatening cardiovascular risks, jeopardizing their clinical applications [83,84].”
BackgroundPharmacodynamic of cyclooxygenase inhibitors in humans
Capone, M. L., Tacconelli, S., Di Francesco, L., Sacchetti, A., Sciulli, M. G., & Patrignani, P. (2007) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.05.019 · Cited by 190
Antirheumatic drug use and the risk of acute myocardial infarction
Suissa, S., Bernatsky, S., & Hudson, M. (2006) · Arthritis Care & Research · doi:10.1002/art.22094 · Cited by 184
Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review
Varrassi, G., Pergolizzi, J. V., Dowling, P., & Paladini, A. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01144-9 · Cited by 180
Nowak-Sliwinska, P., Scapozza, L., & Ruiz i Altaba, A. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.005 · Cited by 183
White, W. B., West, C. R., Borer, J. S., Gorelick, P. B., Lavange, L., Pan, S. X., Weiner, E., & Verburg, K. M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.07.069 · Cited by 186
Yang, K. G. A., Raijmakers, N. J. H., van Arkel, E. R. A., Caron, J. J., Rijk, P. C., Willems, W. J., Zijl, J. A. C., Verbout, A. J., Dhert, W. J. A., & Saris, D. B. F. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.07.008 · Cited by 185
The Role of Inflammation in Colon Cancer
Janakiram, N. B., & Rao, C. V. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_2 · Cited by 151
Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach
P, J. J., Manju, S. L., Ethiraj, K. R., & Elias, G. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.06.003 · Cited by 182
Blaine, T., Moskowitz, R., Udell, J., Skyhar, M., Levin, R., Friedlander, J., Daley, M., & Altman, R. (2008) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/jbjs.f.01116 · Cited by 183
Jordan, J. L., Morgan, T. S., Weinstein, J., & Konstantinou, K. (2002) · Europe PMC (PubMed Central) · Cited by 183
Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview
Thakur, S., Riyaz, B., Patil, A., Kaur, A., Kapoor, B., & Mishra, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.027 · Cited by 179
Diclofenac use and cardiovascular risks: series of nationwide cohort studies
Schmidt, M., Sørensen, H. T., & Pedersen, L. (2018) · BMJ · doi:10.1136/bmj.k3426 · Cited by 177
Adverse drug interactions involving common prescription and over-the-counter analgesic agents
Hersh, E. V., Pinto, A., & Moore, P. A. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.12.003 · Cited by 182
Clinical use and pharmacological properties of selective COX-2 inhibitors
Shi, S., & Klotz, U. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0400-7 · Cited by 179
Neergheen, V. S., Bahorun, T., Taylor, E. W., Jen, L.-S., & Aruoma, O. I. (2010) · Toxicology · doi:10.1016/j.tox.2009.10.010 · Cited by 179
Andersohn, F., Suissa, S., & Garbe, E. (2006) · Circulation · doi:10.1161/circulationaha.105.602425 · Cited by 178
ADAPT Research Group (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010033 · Cited by 176
“92 for rofecoxib compared with placebo [15].”
Donovan, L. M., & Kapur, V. K. (2016) · Sleep · doi:10.5665/sleep.5962 · Cited by 170
Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease
Sudano, I., Flammer, A. J., Périat, D., Enseleit, F., Hermann, M., Wolfrum, M., Hirt, A., Kaiser, P., Hurlimann, D., Neidhart, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.956490 · Cited by 175
Solomon, D. H., Avorn, J., Stürmer, T., Glynn, R. J., Mogun, H., & Schneeweiss, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21887 · Cited by 173
Psaty, B. M., & Kronmal, R. A. (2008) · JAMA · doi:10.1001/jama.299.15.1813 · Cited by 173
Low-dose aspirin and upper gastrointestinal damage:epidemiology, prevention and treatment
Lanas, A., & Scheiman, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x162656 · Cited by 177
Prophylaxis of heterotopic ossification – an updated review
Baird, E. O., & Kang, Q. K. (2009) · Journal of Orthopaedic Surgery and Research · doi:10.1186/1749-799x-4-12 · Cited by 173
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic
de Groot, D. J. A., de Vries, E. G. E., Groen, H. J. M., & de Jong, S. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.07.001 · Cited by 175
The Role of Cyclooxygenase-2 in Colorectal Cancer
Sheng, J., Sun, H., Yu, F.-B., Li, B., Zhang, Y., & Zhu, Y.-T. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.44439 · Cited by 164
“According to the results of large-scale trials, including the Adenomatous Polyp Prevention on Vioxx trial [105], the Adenoma Prevention with Celecoxib trial [104], the Prevention of Colorectal Sporadic Adenomatous Polyps trial [106] and colon polyp prevention trial [107], COXIB are effective for prevention of recurren…”
ResultHyde, C. A. C., & Missailidis, S. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.02.003 · Cited by 168
Recent Advances in the Study on Resveratrol
Nakata, R., Takahashi, S., & Inoue, H. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.35.273 · Cited by 168
Physiologic and pathophysiologic roles of lipid mediators in the kidney
Hao, C.-M., & Breyer, M. D. (2007) · Kidney International · doi:10.1038/sj.ki.5002192 · Cited by 166
Denkert, C., Koch, I., von Keyserlingk, N., Noske, A., Niesporek, S., Dietel, M., & Weichert, W. (2006) · Modern Pathology · doi:10.1038/modpathol.3800645 · Cited by 168
Gridelli, C., Gallo, C., Ceribelli, A., Gebbia, V., Gamucci, T., Ciardiello, F., Carozza, F., Favaretto, A. G., Daniele, B., Galetta, D., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70146-8 · Cited by 169
Genetic Deletion of mPGES-1 Suppresses Intestinal Tumorigenesis
Nakanishi, M., Montrose, D. C., Clark, P., Nambiar, P. R., Belinsky, G. S., Claffey, K. P., Xu, D., & Rosenberg, D. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6100 · Cited by 167
Rolita, L., Spegman, A., Tang, X., & Cronstein, B. N. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12148 · Cited by 164
“to withdrawal of some of these agents at the end of 2004.(15) In response, the American Heart Association pain management recommendations identified the “short-term use of narcotic analgesics as the first step in pain relief management.”
BackgroundFosbøl, E. L., Folke, F., Jacobsen, S., Rasmussen, J. N., Sørensen, R., Schramm, T. K., Andersen, S. S., Rasmussen, S., Poulsen, H. E., Køber, L., et al. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.861104 · Cited by 167
The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research
Chalkidou, K., Tunis, S., Whicher, D., Fowler, R., & Zwarenstein, M. (2012) · Clinical Trials · doi:10.1177/1740774512450097 · Cited by 163
“Cox II inhibitors for the management of arthritis: the Vioxx Gastrointestinal Outcomes Research (VIGOR) [24] and Adenomatous Polyp Prevention on Vioxx (APPROVe) [25] trials”
MethodAnanthakrishnan, A. N., Kaplan, G. G., Bernstein, C. N., Burke, K. E., Lochhead, P. J., Sasson, A. N., Agrawal, M., Tiong, J. H. T., Steinberg, J., Kruis, W., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00021-8 · Cited by 160
Self-citationManagement of hand-foot syndrome induced by capecitabine
Gressett, S. M., Stanford, B. L., & Hardwicke, F. (2006) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155206069242 · Cited by 163
Schmidt, M., Lamberts, M., Olsen, A.-M. S., Fosbøll, E., Niessner, A., Tamargo, J., Rosano, G., Agewall, S., Kaski, J. C., Kjeldsen, K., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv505 · Cited by 164
AJC Editor's Consensus: Psoriasis and Coronary Artery Disease
Friedewald, V. E., Cather, J. C., Gelfand, J. M., Gordon, K. B., Gibbons, G. H., Grundy, S. M., Jarratt, M. T., Krueger, J. G., Ridker, P. M., Stone, N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.004 · Cited by 163
Anti-inflamatórios não esteroides: Efeitos cardiovasculares, cérebro-vasculares e renais
Batlouni, M. (2010) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2010000400019 · Cited by 309
The Price of Truth: How Money Affects the Norms of Science
Resnik, D. B. (2007) · doi:10.1093/acprof:oso/9780195309782.001.0001 · Cited by 160
Chan, F. K. L., Abraham, N. S., Scheiman, J. M., Laine, L., & Agents*, F. T. F. I. W. P. O. G. A. C. E. O. N. A.-I. D. A. A.-P. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02200.x · Cited by 159
“However, enthusiasm for coxibs has waned because of an increase in serious cardiovascular (CV) events with coxibs (3, 4).”
BackgroundMethodCardiometabolic comorbidities in RA and PsA: lessons learned and future directions
Ferguson, L. D., Siebert, S., McInnes, I. B., & Sattar, N. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0256-0 · Cited by 171
Gastrointestinal and cardiovascular adverse events associated with NSAIDs
Domper-Arnal, M. J., Hijos, G., & Lanas, Á. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1965988 · Cited by 176
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.